Semaglutide Clinical Trials: Registered Studies and Status
As of November 2, 2026, ClinicalTrials.gov lists 710 registered studies matching Semaglutide or its known aliases as an intervention.
Summary
- Registered studies
- 710
- Most advanced phase
- Phase 4
- Recruiting or not yet recruiting
- 228
- Most recent start
- 2028-10
- Most frequent lead sponsor
- Novo Nordisk A/S (261)
- Most common status
- Completed
Source: ClinicalTrials.gov, retrieved . Registry searches by name may miss studies that use other identifiers.
Registered studies
| NCT ID | Title | Phase | Status | Enrollment | Start | Lead sponsor |
|---|---|---|---|---|---|---|
| NCT07586150 | Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN) | Not applicable | Not yet recruiting | 140 | 2028-10 | Ludwig-Maximilians - University of Munich |
| NCT07430332 | GLP-1 RA for Stage 1 Type 1 Diabetes | Phase 2 | Not yet recruiting | 15 | 2027-09-01 | Children's Hospital Medical Center, Cincinnati |
| NCT07797036 | Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus | Phase 2 / Phase 3 | Not yet recruiting | 226 | 2027-09-01 | University of Massachusetts, Worcester |
| NCT07754045 | Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults | Phase 2 | Not yet recruiting | 202 | 2027-02-15 | Lumos Pharma |
| NCT07731256 | Semaglutide for Low Back Pain | Phase 2 | Not yet recruiting | 250 | 2027-02-01 | Washington University School of Medicine |
| NCT05714683 | Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | N/A | Not yet recruiting | 600 | 2027-01-31 | Novo Nordisk A/S |
| NCT07879612 | Semaglutide for the Treatment of Cannabis Use Disorder | Phase 2 | Not yet recruiting | 40 | 2027-01-10 | Massachusetts General Hospital |
| NCT07614412 | SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. | Phase 2 | Not yet recruiting | 240 | 2027-01-01 | Ministry of Health, Saudi Arabia |
| NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | Phase 2 | Not yet recruiting | 48 | 2027-01-01 | The Methodist Hospital Research Institute |
| NCT07858331 | Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access | Phase 4 | Not yet recruiting | 880 | 2027-01-01 | Kristin Clemens |
| NCT07462663 | SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer | Phase 4 | Not yet recruiting | 80 | 2027-01 | Hospital Universitari de Bellvitge |
| NCT07760948 | HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide | Phase 2 | Not yet recruiting | 90 | 2026-12-01 | Vanderbilt University Medical Center |
| NCT07770282 | Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome | Phase 3 | Not yet recruiting | 600 | 2026-12-01 | All India Institute of Medical Sciences, Bhubaneswar |
| NCT06977438 | GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward | Phase 4 | Not yet recruiting | 1020 | 2026-11-15 | University of Minnesota |
| NCT07855900 | SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Phase 3 | Not yet recruiting | 350 | 2026-11-07 | Boehringer Ingelheim |
| NCT07866066 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Phase 3 | Not yet recruiting | 1300 | 2026-11-02 | Amgen |
| NCT06546384 | GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | Not applicable | Not yet recruiting | 64 | 2026-11-01 | Insel Gruppe AG, University Hospital Bern |
| NCT07249554 | Combination Therapy for Alcohol Use Disorder | Phase 2 | Not yet recruiting | 45 | 2026-11 | Johns Hopkins University |
| NCT07845994 | SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years | Phase 3 | Not yet recruiting | 50 | 2026-11 | University Hospital, Angers |
| NCT07511543 | Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | Phase 2 | Not yet recruiting | 100 | 2026-10-31 | Population Health Research Institute |
| NCT07900074 | Mechanisms of Weight Loss: Tirzepatide vs Semaglutide | Phase 4 | Recruiting | 80 | 2026-10-31 | McMaster University |
| NCT07592546 | Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss | Phase 4 | Recruiting | 240 | 2026-10-21 | Alain Dagher |
| NCT07840729 | Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants | Phase 1 | Not yet recruiting | 90 | 2026-10-20 | Shanghai JMT-Bio Inc. |
| NCT07889453 | Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide | N/A | Active not recruiting | 650 | 2026-10-15 | LMC Diabetes & Endocrinology Ltd. |
| NCT07874932 | Long-Term Effects of Semaglutide on Body Composition and Performance in Running | Not applicable | Not yet recruiting | 41 | 2026-10-14 | Morten Hostrup, PhD |
| NCT07874971 | Short Term Effects of Semaglutide on Body Composition and Performance | Not applicable | Not yet recruiting | 41 | 2026-10-14 | Morten Hostrup, PhD |
| NCT07881770 | Semaglutide Health Outcomes and Patient Adherence in Australia | N/A | Not yet recruiting | 10000 | 2026-10-13 | Novo Nordisk A/S |
| NCT07891156 | Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. | Phase 2 / Phase 3 | Recruiting | 40 | 2026-10-13 | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| NCT07812597 | A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) | Phase 2 | Not yet recruiting | 210 | 2026-10-12 | Beijing QL Biopharmaceutical Co.,Ltd |
| NCT07900438 | A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China | Phase 4 | Recruiting | 300 | 2026-10-12 | Novo Nordisk A/S |
| NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | Early phase 1 | Recruiting | 30 | 2026-10-10 | University of Arizona |
| NCT07855133 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication | Phase 1 | Recruiting | 60 | 2026-10-05 | Novo Nordisk A/S |
| NCT07423481 | Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity | N/A | Not yet recruiting | 3000 | 2026-10-01 | Nantes University Hospital |
| NCT07772960 | Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes | Phase 1 | Not yet recruiting | 90 | 2026-10-01 | Yale University |
| NCT07872904 | FutureShape Family | Phase 4 | Recruiting | 400 | 2026-10-01 | Signe Torekov |
| NCT07389941 | Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation | Phase 4 | Not yet recruiting | 240 | 2026-10 | University of Luebeck |
| NCT07859137 | Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher | Phase 4 | Not yet recruiting | 100 | 2026-10 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07859150 | Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) | Phase 4 | Not yet recruiting | 104 | 2026-10 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07859163 | Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain | Phase 4 | Not yet recruiting | 100 | 2026-10 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07859176 | Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery | Phase 4 | Not yet recruiting | 100 | 2026-10 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07859189 | Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery | Phase 4 | Not yet recruiting | 100 | 2026-10 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Phase 3 | Recruiting | 660 | 2026-09-30 | Pfizer |
| NCT07845578 | A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight | Phase 1 | Not yet recruiting | 60 | 2026-09-25 | Novo Nordisk A/S |
| NCT07668414 | A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Phase 3 | Recruiting | 650 | 2026-09-22 | Novo Nordisk A/S |
| NCT06073184 | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium | Phase 2 | Recruiting | 71 | 2026-09-17 | GynOncTrials |
| NCT07743983 | A Study of BGM0504 in Early T2DM With Obesity | Phase 3 | Recruiting | 372 | 2026-09-17 | BrightGene Bio-Medical Technology Co., Ltd. |
| NCT07817251 | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Phase 3 | Recruiting | 210 | 2026-09-16 | Novo Nordisk A/S |
| NCT07713992 | Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide | Not applicable | Not yet recruiting | 72 | 2026-09-15 | Tianjin Medical University |
| NCT07653477 | Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | Phase 3 | Recruiting | 956 | 2026-09-07 | The United Bio-Technology (Hengqin) Co., Ltd. |
| NCT06913023 | Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus | Phase 2 / Phase 3 | Not yet recruiting | 37 | 2026-09-05 | University Health Network, Toronto |
| NCT06934655 | Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth | Phase 3 | Recruiting | 150 | 2026-09-01 | Children's Hospital Los Angeles |
| NCT07485062 | Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes | Phase 4 | Not yet recruiting | 164 | 2026-09-01 | Western University, Canada |
| NCT07642635 | Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Not yet recruiting | 30 | 2026-09-01 | Vanderbilt University Medical Center |
| NCT07651319 | Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease | Phase 1 / Phase 2 | Recruiting | 30 | 2026-09-01 | The Methodist Hospital Research Institute |
| NCT07769047 | Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors | Phase 4 | Not yet recruiting | 50 | 2026-09-01 | Mayo Clinic |
| NCT07770152 | Semaglutide in Youth With Autism Spectrum Disorder | Phase 4 | Not yet recruiting | 42 | 2026-09-01 | Children's Hospital Medical Center, Cincinnati |
| NCT07783854 | A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity | Phase 4 | Not yet recruiting | 72 | 2026-09-01 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| NCT07509112 | Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study | Phase 2 | Not yet recruiting | 40 | 2026-09 | Kirby Institute |
| NCT07617155 | GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis | Phase 4 | Not yet recruiting | 396 | 2026-09 | Peking Union Medical College Hospital |
| NCT07622810 | BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity | Phase 3 | Not yet recruiting | 352 | 2026-09 | Carnot Laboratories |
| NCT07628985 | BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | Phase 3 | Not yet recruiting | 374 | 2026-09 | Carnot Laboratories |
| NCT07677995 | Free Fatty Acid Effects In Type 2 Diabetes | Not applicable | Enrolling by invitation | 60 | 2026-09 | University of Ulster |
| NCT07849348 | Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria | Not applicable | Not yet recruiting | 266 | 2026-09 | Peking University People's Hospital |
| NCT07478653 | MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease | Not applicable | Recruiting | 50 | 2026-08-31 | Oelisoa Andriankaja |
| NCT07850765 | Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets | N/A | Completed | 1260 | 2026-08-28 | Novo Nordisk A/S |
| NCT07870538 | A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum | Phase 4 | Recruiting | 96 | 2026-08-26 | Universitaire Ziekenhuizen KU Leuven |
| NCT07781371 | A Retrospective Real-World Cohort Study | N/A | Active not recruiting | 100000 | 2026-08-20 | Novo Nordisk A/S |
| NCT07767175 | A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity | Phase 1 | Recruiting | 142 | 2026-08-12 | Novo Nordisk A/S |
| NCT07770841 | Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight | Phase 3 | Recruiting | 450 | 2026-08-12 | Novo Nordisk A/S |
| NCT07563699 | Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus | Phase 1 / Phase 2 | Recruiting | 24 | 2026-08-09 | Mapi Pharma Ltd. |
| NCT07760532 | Comparing Facial Aging Between Identical Twins With 3D Imaging | N/A | Not yet recruiting | 200 | 2026-08-08 | Ponsky Facial Aesthetics And Plastic Surgery, Llc |
| NCT07282613 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | Phase 3 | Recruiting | 80 | 2026-08-04 | Novo Nordisk A/S |
| NCT07745504 | A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Phase 3 | Recruiting | 285 | 2026-08-04 | Novo Nordisk A/S |
| NCT07695454 | Imaging in Semaglutide Study | N/A | Recruiting | 10 | 2026-07-30 | The Cleveland Clinic |
| NCT07218354 | Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE) | Phase 3 | Recruiting | 622 | 2026-07-28 | VA Office of Research and Development |
| NCT07732426 | Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies | Not applicable | Recruiting | 30 | 2026-07-15 | Seoul National University Hospital |
| NCT07662213 | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus | Phase 3 | Recruiting | 1200 | 2026-07-06 | AstraZeneca |
| NCT07411378 | Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. | Phase 2 | Not yet recruiting | 164 | 2026-07 | Biophytis |
| NCT07430059 | Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | Phase 1 | Not yet recruiting | 20 | 2026-07 | Vivani Medical, Inc |
| NCT07727473 | Preoperative Semaglutide Prior to Radical Prostatectomy | Early phase 1 | Not yet recruiting | 20 | 2026-07 | Banner Health |
| NCT07801820 | Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Phase 2 | Recruiting | 240 | 2026-06-23 | Shanghai Minwei Biotechnology Co., Ltd |
| NCT07668388 | A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Phase 2 | Recruiting | 300 | 2026-06-22 | Novo Nordisk A/S |
| NCT07724340 | A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity | Phase 2 | Active not recruiting | 150 | 2026-06-19 | Antag Therapeutics |
| NCT07728383 | A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity | Phase 4 | Recruiting | 40 | 2026-06-17 | Gila Therapeutics, Inc. |
| NCT07021937 | Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity | Phase 3 | Not yet recruiting | 120 | 2026-06-15 | University of Colorado, Denver |
| NCT07613437 | GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial | Phase 2 | Not yet recruiting | 200 | 2026-06-15 | Chinese University of Hong Kong |
| NCT07673900 | Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants | Phase 1 | Recruiting | 62 | 2026-06-15 | Terrestrial Bio, Inc. |
| NCT07639021 | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Phase 2 | Active not recruiting | 233 | 2026-06-09 | Novo Nordisk A/S |
| NCT07570810 | Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM | Not applicable | Not yet recruiting | 30 | 2026-06-01 | Shanghai Jiao Tong University School of Medicine |
| NCT07282769 | Semaglutide (Wegovy) Treatment for Trichotillomania | Phase 2 | Not yet recruiting | 10 | 2026-06 | University of Chicago |
| NCT07621640 | Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study) | Not applicable | Not yet recruiting | 80 | 2026-06 | Hallym University |
| NCT07858864 | GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | N/A | Recruiting | 42 | 2026-05-30 | Istanbul Saglik Bilimleri University |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Recruiting | 2500 | 2026-05-21 | Novo Nordisk A/S |
| NCT07400107 | AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Phase 3 | Not yet recruiting | 1000 | 2026-05-20 | Novo Nordisk A/S |
| NCT07597018 | A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity | Phase 1 | Recruiting | 234 | 2026-05-18 | Novo Nordisk A/S |
| NCT07272837 | Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass | N/A | Recruiting | 50 | 2026-05-15 | University of Alberta |
| NCT07627074 | Weight Loss in Adults Using Semaglutide (Real-world Study) | N/A | Completed | 237211 | 2026-05-12 | Novo Nordisk A/S |
| NCT07428746 | Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes | Phase 3 | Recruiting | 20 | 2026-05-07 | Emory University |
| NCT07179120 | Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | Phase 2 | Not yet recruiting | 180 | 2026-05-01 | First Affiliated Hospital of Wenzhou Medical University |
| NCT07487103 | Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes | Phase 3 | Not yet recruiting | 478 | 2026-05-01 | Qilu Pharmaceutical Co., Ltd. |
| NCT07633639 | GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Not applicable | Recruiting | 200 | 2026-05-01 | China-Japan Friendship Hospital |
| NCT07523633 | Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder | Phase 2 | Recruiting | 100 | 2026-04-30 | Anders Fink-Jensen, MD, DMSci |
| NCT07588984 | GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study | N/A | Not yet recruiting | 2310 | 2026-04-30 | Noom Inc. |
| NCT07599046 | Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes | Not applicable | Not yet recruiting | 20 | 2026-04-30 | Eighth Affiliated Hospital, Sun Yat-sen University |
| NCT07581145 | Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients | Phase 3 | Recruiting | 52 | 2026-04-24 | Ole Lander Svendsen |
| NCT07653412 | Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. | N/A | Recruiting | 220 | 2026-04-22 | National and Kapodistrian University of Athens |
| NCT07221214 | GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV | Phase 2 | Recruiting | 200 | 2026-04-17 | Vanderbilt University Medical Center |
| NCT07415954 | A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Phase 2 | Recruiting | 270 | 2026-04-17 | Novo Nordisk A/S |
| NCT07527195 | Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) | Phase 1 | Recruiting | 100 | 2026-04-10 | Novo Nordisk A/S |
| NCT07547878 | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Phase 4 | Enrolling by invitation | 64 | 2026-04-08 | Baylor Research Institute |
| NCT07554417 | Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 | Phase 4 | Not yet recruiting | 20 | 2026-04-06 | William Marsh Rice University |
| NCT07466017 | A Study of CS060380 Tablets in Patients With MASH and Obesity | Phase 2 | Active not recruiting | 130 | 2026-04-02 | Cascade Pharmaceuticals, Inc |
| NCT07090343 | Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement | Phase 3 | Not yet recruiting | 826 | 2026-04-01 | Leiden University Medical Center |
| NCT07589322 | Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | Not applicable | Recruiting | 120 | 2026-03-31 | Tri-Service General Hospital (TSGH) |
| NCT07223983 | Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) | Phase 1 | Active not recruiting | 4 | 2026-03-26 | Yale University |
| NCT07446998 | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Phase 2 | Active not recruiting | 239 | 2026-03-26 | Veru Inc. |
| NCT07275697 | Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study | Phase 4 | Recruiting | 200 | 2026-03-23 | Emma Svennberg |
| NCT07505303 | MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Phase 2 | Active not recruiting | 151 | 2026-03-23 | Eccogene |
| NCT07317115 | Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes | Not applicable | Recruiting | 20 | 2026-03-18 | GT Metabolic Solutions, Inc. |
| NCT07361874 | IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion | Not applicable | Recruiting | 75 | 2026-03-05 | University of Texas Southwestern Medical Center |
| NCT07465965 | A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults | Phase 1 | Recruiting | 60 | 2026-03-02 | Shanghai World Leader Pharmaceutical Co., Ltd. |
| NCT06975111 | Focusing on the Menopausal Transition to Improve Mid-Life Women's Health | Phase 2 / Phase 3 | Recruiting | 200 | 2026-03-01 | University of Colorado, Denver |
| NCT07483801 | DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Phase 4 | Not yet recruiting | 112 | 2026-03 | Cambridge University Hospitals NHS Foundation Trust |
| NCT07204249 | Glutide for Ending Methamphetamine | Phase 2 | Recruiting | 162 | 2026-02-26 | San Francisco Department of Public Health |
| NCT07187830 | Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD | N/A | Recruiting | 52 | 2026-02-23 | University of Alberta |
| NCT07424430 | Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes | N/A | Completed | 3392 | 2026-02-20 | LMC Diabetes & Endocrinology Ltd. |
| NCT06836284 | The Evira Study: Additional Support During Obesity Treatment | Not applicable | Recruiting | 40 | 2026-02-13 | Karolinska Institutet |
| NCT07059377 | Semaglutide for Smoking Cessation in Patients With Diabetes | Phase 3 | Recruiting | 100 | 2026-02-13 | Ottawa Heart Institute Research Corporation |
| NCT07456774 | A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China | N/A | Enrolling by invitation | 100000 | 2026-02-13 | Novo Nordisk A/S |
| NCT07325500 | Incretin Microdosing for Cardiometabolic Health in People With HIV | Phase 2 | Recruiting | 30 | 2026-02-12 | The University of Texas Health Science Center, Houston |
| NCT07619508 | Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes. | N/A | Completed | 100000 | 2026-02-10 | Brigham and Women's Hospital |
| NCT07195994 | A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes | Not applicable | Recruiting | 90 | 2026-02-05 | QuickSilver Scientific |
| NCT05689372 | Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | N/A | Enrolling by invitation | 600 | 2026-02-02 | Novo Nordisk A/S |
| NCT07294950 | Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination | Phase 3 | Recruiting | 98 | 2026-02-01 | Mount Sinai Hospital, Canada |
| NCT07323134 | The Effect of Semaglutide on the Intestinal Flora in Obesity | N/A | Not yet recruiting | 40 | 2026-02-01 | Beijing Chao Yang Hospital |
| NCT07391267 | Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. | Not applicable | Not yet recruiting | 90 | 2026-02-01 | Institute of Liver and Biliary Sciences, India |
| NCT06222437 | Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy | Phase 1 | Withdrawn | 0 | 2026-02 | Methodist Health System |
| NCT07417618 | INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | N/A | Completed | 60000 | 2026-01-27 | Brigham and Women's Hospital |
| NCT07390110 | Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL) | N/A | Completed | 25664 | 2026-01-24 | Brigham and Women's Hospital |
| NCT07779343 | OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme | Not applicable | Recruiting | 300 | 2026-01-22 | University of Health Sciences, Algeria |
| NCT07619495 | Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk | N/A | Completed | 120000 | 2026-01-20 | Brigham and Women's Hospital |
| NCT07213466 | Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder | Phase 4 | Recruiting | 100 | 2026-01-19 | Mayo Clinic |
| NCT07242534 | Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. | Phase 4 | Recruiting | 62 | 2026-01-19 | Fundacion Dexeus |
| NCT07040592 | Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide | Phase 2 | Recruiting | 30 | 2026-01-15 | Yale University |
| NCT07227948 | Repurposing Semaglutide for the Treatment of Cocaine Use Disorder | Phase 2 | Recruiting | 75 | 2026-01-15 | The University of Texas Health Science Center, Houston |
| NCT07401992 | Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Phase 4 | Recruiting | 62 | 2026-01-15 | Hospital Universitario Dr. Jose E. Gonzalez |
| NCT07253285 | A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Phase 3 | Recruiting | 460 | 2026-01-08 | Novo Nordisk A/S |
| NCT07172867 | A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM | Phase 2 | Withdrawn | 0 | 2026-01-06 | Halia Therapeutics, Inc. |
| NCT07135245 | Improved Treatment and Monitoring of Alzheimer's Disease | Phase 2 | Not yet recruiting | 180 | 2026-01-01 | Rune Skovgaard Rasmussen |
| NCT07254715 | Effect of Itopride on Semaglutide Gastroparesis | Phase 4 | Completed | 60 | 2026-01-01 | Ain Shams University |
| NCT07640139 | Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | N/A | Enrolling by invitation | 125000 | 2026-01-01 | Indiana University |
| NCT07187856 | Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus | Phase 2 | Not yet recruiting | 80 | 2026-01 | ProGen. Co., Ltd. |
| NCT07284979 | Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Phase 3 | Active not recruiting | 1270 | 2025-12-30 | Kailera |
| NCT07295223 | Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Phase 3 | Recruiting | 44 | 2025-12-30 | Instituto Mexicano del Seguro Social |
| NCT07297589 | Epicardial Cardiac Fat-CT (EPIC-CT) | Phase 3 | Recruiting | 136 | 2025-12-30 | Instituto Mexicano del Seguro Social |
| NCT07319975 | Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity | Not applicable | Not yet recruiting | 48 | 2025-12-29 | Istanbul Galata University |
| NCT07285902 | A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | Phase 3 | Active not recruiting | 572 | 2025-12-25 | Fujian Shengdi Pharmaceutical Co., Ltd. |
| NCT07251556 | GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis | Phase 4 | Not yet recruiting | 40 | 2025-12-01 | Chinese University of Hong Kong |
| NCT07271251 | A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes | Phase 3 | Completed | 267 | 2025-12-01 | Novo Nordisk A/S |
| NCT07302802 | Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice | N/A | Recruiting | 70 | 2025-12-01 | Prof. Dr. Martin Wabitsch |
| NCT07017270 | Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis | Phase 4 | Recruiting | 100 | 2025-11-27 | Unity Health Toronto |
| NCT06954090 | Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study | Phase 4 | Enrolling by invitation | 50 | 2025-11-20 | Steno Diabetes Center Copenhagen |
| NCT07871799 | ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging | Phase 2 | Completed | 31 | 2025-11-17 | Sheba Medical Center |
| NCT07280221 | WEgovy Real World Assessment of Weight Loss in Korea | N/A | Enrolling by invitation | 500 | 2025-11-10 | Novo Nordisk A/S |
| NCT07225816 | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | Phase 1 | Recruiting | 71 | 2025-11-07 | Novo Nordisk A/S |
| NCT07202247 | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Phase 2 | Recruiting | 60 | 2025-11-05 | City of Hope Medical Center |
| NCT07820111 | Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial | Phase 3 | Completed | 159 | 2025-10-18 | Zagazig University |
| NCT07220629 | Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) | Phase 2 | Completed | 82 | 2025-10-02 | Rezera (formerly NodThera Limited) |
| NCT06801015 | Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Phase 4 | Active not recruiting | 30 | 2025-10-01 | Mayo Clinic |
| NCT07073053 | The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms | Phase 4 | Not yet recruiting | 60 | 2025-10-01 | Taipei Veterans General Hospital, Taiwan |
| NCT06909006 | Semaglutide Treatment in Type 1 Diabetes | Phase 3 | Not yet recruiting | 122 | 2025-10 | Nordsjaellands Hospital |
| NCT07154238 | Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study. | N/A | Enrolling by invitation | 2546 | 2025-09-26 | Novo Nordisk A/S |
| NCT07184086 | A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | Phase 1 | Active not recruiting | 80 | 2025-09-26 | Novo Nordisk A/S |
| NCT07200622 | Oral Semaglutide in Patients With Alzheimer's Disease | Phase 2 | Not yet recruiting | 60 | 2025-09-25 | Imperial College London |
| NCT07150975 | Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | Phase 3 | Recruiting | 420 | 2025-09-23 | Gan & Lee Pharmaceuticals. |
| NCT07216651 | WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults | N/A | Completed | 20 | 2025-09-23 | Closed Loop Medicine |
| NCT07152756 | Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores | N/A | Not yet recruiting | 418 | 2025-09-15 | Fudan University |
| NCT07156591 | Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention | N/A | Not yet recruiting | 460 | 2025-09-15 | Fudan University |
| NCT07165158 | The Effect of Semaglutide on Bone Health | Phase 4 | Not yet recruiting | 150 | 2025-09-15 | The First Affiliated Hospital of Xiamen University |
| NCT07136714 | Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity | Phase 4 | Recruiting | 116 | 2025-09-11 | Nordsjaellands Hospital |
| NCT07314684 | GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM | Phase 4 | Recruiting | 80 | 2025-09-08 | Federico II University |
| NCT07171723 | Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment | Early phase 1 | Completed | 24 | 2025-09-01 | University Hospital, Gentofte, Copenhagen |
| NCT07139548 | A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | Phase 3 | Not yet recruiting | 600 | 2025-08-31 | Guangdong Raynovent Biotech Co., Ltd |
| NCT07141914 | A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World | N/A | Completed | 285327 | 2025-08-29 | Novo Nordisk A/S |
| NCT07112872 | A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes | Phase 2 | Active not recruiting | 330 | 2025-08-19 | Hoffmann-La Roche |
| NCT07091500 | Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity | Not applicable | Recruiting | 40 | 2025-08-11 | Washington University School of Medicine |
| NCT07115069 | Comparison of Body Composition Changes With Weight Loss Interventions | N/A | Active not recruiting | 60 | 2025-08-09 | Vanderbilt University Medical Center |
| NCT07081178 | A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany). | N/A | Terminated | 100 | 2025-08-08 | Novo Nordisk A/S |
| NCT06691243 | Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV | Phase 2 | Active not recruiting | 40 | 2025-08-07 | University of Maryland, Baltimore |
| NCT06885736 | LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | Not applicable | Recruiting | 232 | 2025-08-07 | Dasman Diabetes Institute |
| NCT07621419 | Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin | N/A | Recruiting | 145 | 2025-08-04 | Hospital Italiano de Buenos Aires |
| NCT07046273 | Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes | Phase 3 | Not yet recruiting | 496 | 2025-08-01 | Shandong New Time Pharmaceutical Co., LTD |
| NCT07065383 | Rebalancing the Fat Content of the Heart and Muscles | Not applicable | Recruiting | 60 | 2025-08-01 | University of Aberdeen |
| NCT07096739 | Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1 | Not applicable | Completed | 20 | 2025-08-01 | Kate Farms Inc |
| NCT07513168 | Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults | Phase 4 | Recruiting | 60 | 2025-08-01 | Asian Institute Of Medical Sciences |
| NCT07073417 | A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) | Phase 2 | Active not recruiting | 163 | 2025-07-28 | Hangzhou Sciwind Biosciences Co., Ltd. |
| NCT07254572 | Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes | Phase 4 | Recruiting | 300 | 2025-07-10 | National Institute of Cardiology, Warsaw, Poland |
| NCT07847593 | Probiotics in Obese Patients Treated With Semaglutide | Not applicable | Completed | 102 | 2025-07-09 | Nordic Biotic Sp. z o.o. |
| NCT07064486 | A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | Phase 3 | Active not recruiting | 152 | 2025-07-04 | BrightGene Bio-Medical Technology Co., Ltd. |
| NCT06908694 | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy | Phase 4 | Active not recruiting | 20 | 2025-07-02 | Hamilton Health Sciences Corporation |
Showing 200 of 710 studies, most recent start first.
Method and limitations
- Data source: ClinicalTrials.gov API v2, intervention search.
- Query used:
Semaglutide OR Ozempic OR Wegovy OR Rybelsus OR NN9535 - Retrieved: November 2, 2026. Refreshed weekly; changes are reviewed before publication.
- Studies registered only under other names, sponsor codes, or in other registries may be missing.
- A match on name does not mean the study tested this peptide alone; some studies include it as a comparator or combination.
- Status values are reported by sponsors and may be out of date.